Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2016 by Massachusetts General Hospital
Sponsor:
Collaborator:
Autism Speaks
Information provided by (Responsible Party):
Christopher John McDougle, M.D., Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01302964
First received: August 25, 2010
Last updated: March 13, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2018
  Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)